BACKGROUND: To analyse prospectively the effect of calcium or calcium+D supplementation on coronary heart disease (CHD) in 52-62-year-old women. METHODS AND RESULTS: 10,555 52-62-year-old women from the population-based Kuopio Osteoporosis Risk Factor and Prevention Study (OSTPRE) who did not have CHD at baseline were followed for nearly 7 years in 1994-2001. Information about use of calcium supplements and health events was obtained from two repeated questionnaires in 1989 and 1994. Information about causes of death during the follow-up was obtained from the Statistics Finland. Information about CHD and other disease morbidity before and during the follow-up was obtained from the Registry of Specially Refunded Drugs of the Finnish Social Insurance Institution (SII). Cox's proportional-hazards models were used to estimate the risk of CHD morbidity related to the use of calcium supplements. At baseline, 2723 women reported current use of calcium or calcium+D supplementation. During the follow-up, CHD was diagnosed in 513 women. Compared to non-users of calcium/calcium+D supplements, the multivariate adjusted hazard ratio (HR) of CHD was 1.24 (95% CI 1.02-1.52) in women who used these supplements. The multivariate adjusted HR for CHD morbidity in postmenopausal women who used calcium/calcium+D supplements was 1.26 (95% CI 1.01-1.57). CONCLUSIONS: Calcium or calcium+D supplementation appears to increase the risk of CHD among women before old age.
BACKGROUND: To analyse prospectively the effect of calcium or calcium+D supplementation on coronary heart disease (CHD) in 52-62-year-old women. METHODS AND RESULTS: 10,555 52-62-year-old women from the population-based Kuopio Osteoporosis Risk Factor and Prevention Study (OSTPRE) who did not have CHD at baseline were followed for nearly 7 years in 1994-2001. Information about use of calcium supplements and health events was obtained from two repeated questionnaires in 1989 and 1994. Information about causes of death during the follow-up was obtained from the Statistics Finland. Information about CHD and other disease morbidity before and during the follow-up was obtained from the Registry of Specially Refunded Drugs of the Finnish Social Insurance Institution (SII). Cox's proportional-hazards models were used to estimate the risk of CHD morbidity related to the use of calcium supplements. At baseline, 2723 women reported current use of calcium or calcium+D supplementation. During the follow-up, CHD was diagnosed in 513 women. Compared to non-users of calcium/calcium+D supplements, the multivariate adjusted hazard ratio (HR) of CHD was 1.24 (95% CI 1.02-1.52) in women who used these supplements. The multivariate adjusted HR for CHD morbidity in postmenopausal women who used calcium/calcium+D supplements was 1.26 (95% CI 1.01-1.57). CONCLUSIONS:Calcium or calcium+D supplementation appears to increase the risk of CHD among women before old age.
Authors: E Barrett-Connor; S W Wade; R W Downs; T Ganiats; M Hochberg; R R Recker; B S Stolshek Journal: Osteoporos Int Date: 2015-04-16 Impact factor: 4.507
Authors: M Kärkkäinen; M Tuppurainen; K Salovaara; L Sandini; T Rikkonen; J Sirola; R Honkanen; J Jurvelin; E Alhava; H Kröger Journal: Osteoporos Int Date: 2010-03-04 Impact factor: 4.507
Authors: Robert P Heaney; Stephen Kopecky; Kevin C Maki; John Hathcock; Douglas Mackay; Taylor C Wallace Journal: Adv Nutr Date: 2012-11-01 Impact factor: 8.701
Authors: W Zhou; L Langsetmo; C Berger; S Poliquin; N Kreiger; S I Barr; S M Kaiser; R G Josse; J C Prior; T E Towheed; T Anastassiades; K S Davison; C S Kovacs; D A Hanley; E A Papadimitropoulos; D Goltzman Journal: J Musculoskelet Neuronal Interact Date: 2013-12 Impact factor: 2.041
Authors: Lisa Langsetmo; Claudie Berger; Nancy Kreiger; Christopher S Kovacs; David A Hanley; Sophie A Jamal; Susan J Whiting; Jacques Genest; Suzanne N Morin; Anthony Hodsman; Jerilynn C Prior; Brian Lentle; Millan S Patel; Jacques P Brown; Tassos Anastasiades; Tanveer Towheed; Robert G Josse; Alexandra Papaioannou; Jonathan D Adachi; William D Leslie; K Shawn Davison; David Goltzman Journal: J Clin Endocrinol Metab Date: 2013-05-23 Impact factor: 5.958